Search results for "TUMORS"

showing 10 items of 1138 documents

Symptomatic COVID-19 in advanced-cancer patients treated with immune-checkpoint inhibitors. Prospective analysis from a multicentre observational tri…

2020

Background:This prospective, multicentre, observational INVIDIa-2 study is investigating the clinical efficacy of influenza vaccination in advanced-cancer patients receiving immune-checkpoint inhibitors (ICIs), enrolled in 82 Italian centres, from October 2019 to January 2020. The primary endpoint was the incidence of influenza-like illness (ILI) until 30 April 2020. All the ILI episodes, laboratory tests, complications, hospitalizations and pneumonitis were recorded. Therefore, the study prospectively recorded all the COVID-19 ILI events.Patients and methods:Patients were included in this non-prespecified COVID-19 analysis, if alive on 31 January 2020, when the Italian government declared …

0301 basic medicinemedicine.medical_specialtymedicine.medical_treatmentimmune-checkpoint inhibitorsinfluenza-like illnesslcsh:RC254-28203 medical and health sciences0302 clinical medicineCancer immunotherapyInternal medicineMedicineProspective cohort studyCancer stagingOriginal ResearchInfluenza-like illnessbusiness.industrySARS-CoV-2virus diseasesCOVID-19Immunotherapycancer patients; COVID-19; immune-checkpoint inhibitors; influenza-like illness; SARS-CoV-2lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensmedicine.diseaseComorbidityVaccination030104 developmental biologyOncology030220 oncology & carcinogenesisObservational studybusinesscancer patients
researchProduct

A liposomal RNA vaccine inducing neoantigen-specific CD4+ T cells augments the antitumor activity of local radiotherapy in mice

2020

Antigen-encoding, lipoplex-formulated RNA (RNA-LPX) enables systemic delivery to lymphoid compartments and selective expression in resident antigen-presenting cells. We report here that the rejection of CT26 tumors, mediated by local radiotherapy (LRT), is further augmented in a CD8+ T cell-dependent manner by an RNA-LPX vaccine that encodes CD4+ T cell-recognized neoantigens (CD4 neoantigen vaccine). Whereas CD8+ T cells induced by LRT alone were primarily directed against the immunodominant gp70 antigen, mice treated with LRT plus the CD4 neoantigen vaccine rejected gp70-negative tumors and were protected from rechallenge with these tumors, indicating a potent poly-antigenic CD8+ T cell r…

0301 basic medicinemedicine.medical_treatmentT cellImmunology03 medical and health sciences0302 clinical medicineAntigenmedicineImmunology and Allergyrna-lpxcd4+ t cellsradiotherapyRC254-282Antitumor activityLiposomeintegumentary systembusiness.industryNeoplasms. Tumors. Oncology. Including cancer and carcinogensRNARC581-607Radiation therapy030104 developmental biologymedicine.anatomical_structureOncologyLocal radiotherapy030220 oncology & carcinogenesisCancer researchImmunologic diseases. Allergybusinesscancer vaccinesneoantigensCD8OncoImmunology
researchProduct

Treatment of advanced gastroenteropancreatic neuroendocrine neoplasia, are we on the way to personalised medicine?

2021

Gastroenteropancreatic neuroendocrine neoplasia (GEPNEN) comprises clinically as well as prognostically diverse tumour entities often diagnosed at late stage. Current classification provides a uniform terminology and a Ki67-based grading system, thereby facilitating management. Advances in the study of genomic and epigenetic landscapes have amplified knowledge of tumour biology and enhanced identification of prognostic and potentially predictive treatment subgroups. Translation of this genomic and mechanistic biology into advanced GEPNEN management is limited. ‘Targeted’ treatments such as somatostatin analogues, peptide receptor radiotherapy, tyrosine kinase inhibitors and mammalian target…

0301 basic medicinemedicine.medical_treatmentcancer geneticsNeuroendocrine tumorsBioinformaticschemotherapyMolecular oncologyEpigenesis Genetic03 medical and health sciences0302 clinical medicinemolecular oncologyStomach NeoplasmsIntestinal NeoplasmsBiomarkers TumormedicineHumanscancer genetics; chemotherapy; immunotherapy; molecular oncology; neuroendocrine tumorsEpigeneticsPrecision Medicine610 Medicine & healthbusiness.industryGastroenterologyImmunotherapymedicine.diseasePancreatic NeoplasmsRadiation therapyClinical trial030104 developmental biologyTargeted drug delivery030220 oncology & carcinogenesis570 Life sciences; biologyIdentification (biology)immunotherapyneuroendocrine tumorsbusiness
researchProduct

The Role of p53 Signaling in Colorectal Cancer.

2021

Simple Summary The transcription factor p53 is a crucial tumor suppressor that regulates diverse cellular responses to protect against cancer development. Deactivating p53 signaling either by altering p53 regulators or by p53 mutations occurs frequently in human colorectal carcinoma (CRC). Forty-three percent of CRCs harbor p53 mutations that reduce wild-type p53 tumor suppressor activity and often provide neo-morphic functions, which contribute to tumorigenesis. In this review, we summarize wild-type p53 signaling, how it can be deregulated in CRC, and the functional and phenotypical effects of p53 mutations. We also discuss current therapeutic strategies of targeting p53. Abstract The tra…

0301 basic medicinewild type p53Cancer ResearchDNA repairCellular differentiationcolorectal cancerReview03 medical and health sciences0302 clinical medicinemedicineTranscription factorRC254-282gain-of-functionbiologyCell growthmutant p53CancerNeoplasms. Tumors. Oncology. Including cancer and carcinogensmedicine.diseaseUbiquitin ligasep53 signaling030104 developmental biologyOncology030220 oncology & carcinogenesisCancer cellbiology.proteinCancer researchMdm2cancer therapyp53 pathwayCancers
researchProduct

Cognitively-Based Compassion Training (CBCT (R)) in Breast Cancer Survivors: A Randomized Clinical Trial Study

2018

Breast cancer (BC) requires a significant psychological adaptation once treatment is finished. There is growing evidence of how compassion training enhances psychological and physical well-being, however, there are very few studies analyzing the efficacy of compassion-based Interventions on BC survivors. Objective. To study the efficacy of the CognitivelyBased Compassion Training (CBCT) protocol in a BC survivor sample on quality of life, psychological well-being, fear of cancer recurrence, self-compassion, and compassion domains and mindfulness facets. Furthermore, enrollment, adherence, and satisfaction with the intervention were also analyzed. Methods. A randomized clinical trial was des…

050103 clinical psychologyanimal structuresmedia_common.quotation_subjectfear of cancer recurrenceContext (language use)Compassionlaw.invention03 medical and health sciences0302 clinical medicineBreast cancerbreast cancerRandomized controlled triallawwell-beingSurvivorship curvePsychological adaptationmedicine0501 psychology and cognitive sciencescontemplative trainingRC254-282media_commonbusiness.industry05 social sciencescompassion trainingNeoplasms. Tumors. Oncology. Including cancer and carcinogensmedicine.diseaseself-compassionComplementary and alternative medicineOncology030220 oncology & carcinogenesisWell-beingbusinesssurvivorshipSelf-compassionClinical psychology
researchProduct

Integrated CGH/WES Analyses Advance Understanding of Aggressive Neuroblastoma Evolution: A Case Study

2021

Neuroblastoma (NB) is the most common extra-cranial malignancy in preschool children. To portray the genetic landscape of an overly aggressive NB leading to a rapid clinical progression of the disease, tumor DNA collected pre- and post-treatment has been analyzed. Array comparative genomic hybridization (aCGH), whole-exome sequencing (WES), and pharmacogenetics approaches, respectively, have identified relevant copy number alterations (CNAs), single nucleotide variants (SNVs), and polymorphisms (SNPs) that were then combined into an integrated analysis. Spontaneously formed 3D tumoroids obtained from the recurrent mass have also been characterized. The results prove the power of combining C…

3D tumoroids; Array CGH; Clonal evolution; Neuroblastoma; Pharmacogenetics; Recurrent tumor; Single nucleotide variants; Whole exome sequencing; Child Preschool; Disease Progression; Drug Resistance Neoplasm; Fatal Outcome; Humans; Immunophenotyping; Neuroblastoma; Polymorphism Single Nucleotide; Comparative Genomic Hybridization; Whole Exome SequencingQH301-705.5Drug Resistanceclonal evolutionCase Report3D tumoroidsSingle-nucleotide polymorphismDiseaseComputational biologyBiologyMalignancyPolymorphism Single NucleotideSomatic evolution in cancerImmunophenotypingwhole exome sequencingNeuroblastomaFatal OutcomeNeuroblastomaExome SequencingmedicineHumansarray CGHrecurrent tumorPolymorphismBiology (General)ChildPreschoolExome sequencingTumorsComparative Genomic HybridizationSingle NucleotideGeneral Medicinemedicine.diseaseSingle nucleotide variantsDrug Resistance NeoplasmPharmacogeneticsChild PreschoolDisease ProgressionFarmacogenèticaNeoplasmPharmacogeneticsComparative genomic hybridization
researchProduct

Use of a Perioperative Web-Based Exercise Program for a Patient with Barrett’s Carcinoma Scheduled for Esophagectomy

2019

A poor preoperative functional capacity increases the perioperative risk. Therefore, a web-based exercise approach has been initiated for a careful supervision and individual support of patients during their perioperative cancer therapy. Here, we present the data of a 57-year-old patient, scheduled for esophagectomy. Beside a five-week neoadjuvant chemoradiotherapy (CRT), the patient performed 10 weeks of a web-based prehabilitation exercise training (preconditioning) and continued the exercise program for 14 weeks after surgery. The patient performed 42 of 44 recommended training sessions in the preconditioning period in his home environment. This corresponds to a mean of 131 (±38) min of …

796 Sportexerciseperioperative carebarrett’s carcinomapreconditioningweb-basedCase ReportBarrett's carcinomaesophageal cancerprehabilitationlcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogenslcsh:RC254-282796 Athletic and outdoor sports and gamesCase Reports in Oncology
researchProduct

Time-Varying mHAP-III Is the Most Accurate Predictor of Survival in Patients with Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization

2021

<b><i>Introduction:</i></b> The prognosis of patients undergoing transarterial chemoembolization (TACE) is extremely variable, and a confounding factor is that TACE is often repeated several times. We retrospectively evaluated the accuracy of different prognostic scores and staging systems in estimating overall survival (OS) in patients with hepatocellular carcinoma (HCC). <b><i>Methods:</i></b> An analysis considering prognostic models as time-varying variables was performed, calculating OS from the time of TACE to the time of the subsequent treatment. Total follow-up time for each patient was therefore split into several observation times ac…

ALBI grade; Barcelona Clinic Liver Cancer; Cancer of the Liver Italian Program; ITALICA staging system; MESIAHmedicine.medical_specialtylcsh:RC254-282GastroenterologyALBI gradeBarcelona Clinic Liver CancerInternal medicineMedicineIn patientCancer of the Liver Italian ProgramITALICA staging systemRadiologic ResponseSettore MED/12 - GastroenterologiaOriginal PaperHepatologybusiness.industryProportional hazards modelConfoundingHazard ratiolcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensmedicine.diseaseMESIAHOncologyHepatocellular carcinomaAkaike information criterionbusinessLiver cancer
researchProduct

Acute Promyelocytic Leukemia during Pregnancy: A Systematic Review of the Literature

2020

The management of pregnant women with acute promyelocytic leukemia (APL) is a challenging situation where limited evidence-based information is available. We performed a systematic literature review to analyze the outcomes reported for both mother and fetus when APL is diagnosed during pregnancy. PubMed, Scopus and Web of Science databases were systematically searched to identify studies reporting cases of APL during pregnancy. Sixty-six articles met the eligibility criteria (53 single case reports). Ninety-two patients were eligible for induction therapy, with most them being treated with all-trans retinoic acid alone (32%) or combined with chemotherapy (43%), while the remaining patients …

Acute promyelocytic leukemiaCancer Researchmedicine.medical_specialtyAbortionchemotherapylcsh:RC254-282Article03 medical and health sciences0302 clinical medicineObstetrics and gynaecologymedicineNeonatologyPregnancyFetal viabilityRespiratory distressObstetricsbusiness.industryGestational ageacute promyelocytic leukemialcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensmedicine.diseaseall-trans retinoic acidarsenic trioxideOncology030220 oncology & carcinogenesispregnancybusiness030215 immunologyCancers
researchProduct

Genotypic and Phenotypic Characteristics of Acute Promyelocytic Leukemia Translocation Variants.

2020

Acute promyelocytic leukemia (APL) is a special disease entity of acute myeloid leukemia (AML). The clinical use of all-trans retinoic acid (ATRA) has transformed APL into the most curable form of AML. The majority of APL cases are characterized by the fusion gene PML-RARA. Although the PML-RARA fusion gene can be detected in almost all APL cases, translocation variants of APL have been reported. To date, this is the most comprehensive review of these translocations, discussing 15 different variants. Reviewed genes involved in APL variants include: ZBTB16, NPM, NuMA, STAT5b, PRKAR1A, FIP1L1, BCOR, NABP1, TBLR1, GTF2I, IRF2BP2, FNDC3B, ADAMDTS17, STAT3, and TFG. The genotypic and phenotypic …

Acute promyelocytic leukemiaGenotypeSTAT5BChromosomal translocationFusion geneslcsh:RC254-282Translocation GeneticFusion gene03 medical and health sciences0302 clinical medicineLeukemia Promyelocytic AcuteAcute promyelocytic leukemiaimmune system diseasesMedicineHumansneoplasmsPRKAR1AGeneRARAlcsh:RC633-647.5business.industryMyeloid leukemialcsh:Diseases of the blood and blood-forming organsHematologyGeneral Medicinelcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensmedicine.diseaseFusion proteinNeoplasm ProteinsOncology030220 oncology & carcinogenesisCancer researchbusinessChimeric proteins030215 immunologyHematology/oncology and stem cell therapy
researchProduct